{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:20:22Z","timestamp":1772724022074,"version":"3.50.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,3,21]],"date-time":"2015-03-21T00:00:00Z","timestamp":1426896000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pharmacol Rep"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s40495-015-0029-7","type":"journal-article","created":{"date-parts":[[2015,3,20]],"date-time":"2015-03-20T06:23:03Z","timestamp":1426832583000},"page":"365-372","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Extracting the Benefit of Nexrutine\u00ae for Cancer Prevention"],"prefix":"10.1007","volume":"1","author":[{"given":"Suleman S.","family":"Hussain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darpan","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Addanki P.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,21]]},"reference":[{"key":"29_CR1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9\u201329.","journal-title":"CA Cancer J Clin"},{"key":"29_CR2","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrd4068","volume":"12","author":"T Dominic","year":"2013","unstructured":"Dominic T, Kimberley C. Advances in prostate cancer treatment. Nat Rev Drug Discov. 2013;12:823\u20134. This review highlights the recently approved therapies and late-stage pipeline products for prostate cancer treatment.","journal-title":"Nat Rev Drug Discov"},{"key":"29_CR3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2011.07.003","volume":"60","author":"DL Kate","year":"2011","unstructured":"Kate DL, James WFC. Gastrointestinal toxicity following radiotherapy for prostate cancer: a ring of fire. Eur Urol. 2011;60:917\u20139.","journal-title":"Eur Urol"},{"key":"29_CR4","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","volume":"358","author":"MG Sanda","year":"2008","unstructured":"Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250\u201361.","journal-title":"N Engl J Med"},{"key":"29_CR5","doi-asserted-by":"crossref","first-page":"13958","DOI":"10.3390\/ijms140713958","volume":"14","author":"L Yin","year":"2012","unstructured":"Yin L, Hu Q, Hartmann RW. Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci. 2012;14:13958\u201378.","journal-title":"Int J Mol Sci"},{"key":"29_CR6","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65:1180\u201392.","journal-title":"Int J Clin Pract"},{"key":"29_CR7","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/2159-8290.CD-13-0142","volume":"3","author":"M Korpal","year":"2013","unstructured":"Korpal M, Korn J, Gao X, Rakiec D, Ruddy D, Doshi S, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 2013;3:1030\u201343. F876L mutation in androgen receptor was identified to be responsible for antagonist to agonist shift of enzalutamide leading to progression to CRPC.","journal-title":"Cancer Discov"},{"key":"29_CR8","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","volume":"3","author":"J Joseph","year":"2013","unstructured":"Joseph J, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 2013;3:1020\u20139. F876L missense mutation in the AR was found to cause resistance to ARN-509 and could be detected in plasma of ARN-509\u2013treated patients having progressive CRPC.","journal-title":"Cancer Discov"},{"key":"29_CR9","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1158\/1078-0432.CCR-06-1104","volume":"12","author":"G Kelloff","year":"2006","unstructured":"Kelloff G, Lippman S, Dannenberg A, Sigman C, Pearce H, Reid B, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer\u2014a plan to move forward. Clin Cancer Res. 2006;12:3661\u201397.","journal-title":"Clin Cancer Res"},{"key":"29_CR10","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.eururo.2013.05.029","volume":"64","author":"C Barbieri","year":"2013","unstructured":"Barbieri C, Bangma C, Bjartell A, Catto J, Culig Z, Gr\u00f6nberg H, et al. The mutational landscape of prostate cancer. Eur Urol. 2013;64:567\u201376. This paper characterized the mutations in 50 heavily pretreated metastatic CRPC patients to elucidate resistance mechanisms.","journal-title":"Eur Urol"},{"key":"29_CR11","first-page":"2699","volume":"36","author":"MB Sporn","year":"1976","unstructured":"Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res. 1976;36:2699\u2013702.","journal-title":"Cancer Res"},{"key":"29_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.2013.280","volume":"109","author":"W Steward","year":"2013","unstructured":"Steward W, Brown K. Cancer chemoprevention: a rapidly evolving field. Br J Cancer. 2013;109:1\u20137. This review outlines the current developments in chemoprevention and provides insights for effective design of chemoprevention clinical trials.","journal-title":"Br J Cancer"},{"key":"29_CR13","first-page":"1","volume":"4","author":"G Kelloff","year":"1995","unstructured":"Kelloff G, Johnson J, Crowell J, Boone C, DeGeorge J, Steele V, et al. Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomark Prev. 1995;4:1\u201310.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"29_CR14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bpg.2011.10.012","volume":"25","author":"X Wu","year":"2011","unstructured":"Wu X, Patterson S, Hawk E. Chemoprevention\u2014history and general principles. Best Pract Res Clin Gastroenterol. 2011;25:445\u201359.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"29_CR15","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","volume":"362","author":"G Andriole","year":"2010","unstructured":"Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192\u2013202.","journal-title":"N Engl J Med"},{"key":"29_CR16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","volume":"349","author":"IM Thompson","year":"2003","unstructured":"Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215\u201324.","journal-title":"N Engl J Med"},{"key":"29_CR17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1215932","volume":"369","author":"I Thompson","year":"2013","unstructured":"Thompson I, Goodman P, Tangen C, Parnes H, Minasian L, Godley P, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013;369:603\u201310. This was a 18-year follow-up of the prostate cancer prevention trial which showed no significant difference in overall survival after administration of finasteride.","journal-title":"N Engl J Med"},{"key":"29_CR18","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/jnci\/djj307","volume":"98","author":"IM Thompson","year":"2006","unstructured":"Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98:1128\u201333.","journal-title":"J Natl Cancer Inst"},{"key":"29_CR19","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.juro.2007.01.071","volume":"177","author":"IM Thompson","year":"2007","unstructured":"Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM, et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol. 2007;177:1749\u201352.","journal-title":"J Urol"},{"key":"29_CR20","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nrurol.2010.102","volume":"7","author":"V Venkateswaran","year":"2010","unstructured":"Venkateswaran V, Klotz L. Diet and prostate cancer: mechanisms of action and implications for chemoprevention. Nat Rev Urol. 2010;7:442\u201353.","journal-title":"Nat Rev Urol"},{"key":"29_CR21","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.bcp.2011.12.027","volume":"83","author":"D Thapa","year":"2012","unstructured":"Thapa D, Ghosh R. Antioxidants for prostate cancer chemoprevention: challenges and opportunities. Biochem Pharmacol. 2012;83:1319\u201330. This review discussed the preclinical and clinical studies of various antioxidants in prostate cancer chemoprevention and highlighted factors to be considered while designing chemoprevention trials.","journal-title":"Biochem Pharmacol"},{"key":"29_CR22","doi-asserted-by":"crossref","unstructured":"Tomomi K. East meets West: ethnic differences in prostate cancer epidemiology between East Asians and Caucasians. Chin J Cancer. 2012;31(9):421\u201329.","DOI":"10.5732\/cjc.011.10324"},{"key":"29_CR23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/aje\/kwm249","volume":"167","author":"N Kurahashi","year":"2008","unstructured":"Kurahashi N, Sasazuki S, Iwasaki M, Inoue M, Tsugane S, Group JS. Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol. 2008;167:71\u20137.","journal-title":"Am J Epidemiol"},{"key":"29_CR24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10552-007-9088-3","volume":"19","author":"BA Miller","year":"2008","unstructured":"Miller BA, Chu KC, Hankey BF, Ries LA. Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U.S. Cancer Causes Control. 2008;19:227\u201356.","journal-title":"Cancer Causes Control"},{"issue":"15","key":"29_CR25","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/jnci\/djt157","volume":"105","author":"S Gomez","year":"2013","unstructured":"Gomez S, Noone A-M, Lichtensztajn D, Scoppa S, Gibson J, Liu L, et al. Cancer incidence trends among Asian American populations in the United States, 1990 to 2008. J Natl Cancer Inst. 2013;105(15):1096\u2013110.","journal-title":"J Natl Cancer Inst"},{"key":"29_CR26","doi-asserted-by":"crossref","first-page":"8152","DOI":"10.1200\/JCO.2005.03.1492","volume":"23","author":"J Chan","year":"2005","unstructured":"Chan J, Gann P, Giovannucci E. Role of diet in prostate cancer development and progression. J Clin Oncol. 2005;23:8152\u201360.","journal-title":"J Clin Oncol"},{"key":"29_CR27","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/j.1464-410X.2010.09897.x","volume":"107","author":"S Hori","year":"2011","unstructured":"Hori S, Butler E, McLoughlin J. Prostate cancer and diet: food for thought? BJU Int. 2011;107:1348\u201359.","journal-title":"BJU Int"},{"issue":"2","key":"29_CR28","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/CEJ.0b013e3283647394","volume":"23","author":"W Gathirua-Mwangi","year":"2013","unstructured":"Gathirua-Mwangi W, Zhang J. Dietary factors and risk for advanced prostate cancer. Eur J Cancer Prev. 2013;23(2):96\u2013109.","journal-title":"Eur J Cancer Prev"},{"key":"29_CR29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.2008.864","volume":"301","author":"SM Lippman","year":"2009","unstructured":"Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301:39\u201351.","journal-title":"JAMA"},{"key":"29_CR30","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1158\/1940-6207.CAPR-10-0259","volume":"4","author":"JR Marshall","year":"2011","unstructured":"Marshall JR, Ip C, Romano K, Fetterly G, Fakih M, Jovanovic B, et al. Methyl selenocysteine: single-dose pharmacokinetics in men. Cancer Prev Res (Phila). 2011;4:1938\u201344.","journal-title":"Cancer Prev Res (Phila)"},{"key":"29_CR31","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1158\/1055-9965.EPI-13-1340","volume":"23","author":"JM Schenk","year":"2014","unstructured":"Schenk JM, Till CA, Tangen CM, Goodman PJ, Song X, Torkko KC, et al. Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev. 2014;23:1484\u201393.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"29_CR32","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1055-9965.EPI-14-0115","volume":"23","author":"AR Kristal","year":"2014","unstructured":"Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, et al. Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomark Prev. 2014;23:1494\u2013504.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"29_CR33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1021\/np200906s","volume":"75","author":"D Newman","year":"2012","unstructured":"Newman D, Cragg G. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 2012;75:311\u201335. This review lays out detailed statistics of natural products which were approved in the past 30 years for cacner treatment.","journal-title":"J Nat Prod"},{"issue":"1","key":"29_CR34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2004.04.010","volume":"51","author":"B Premalatha","year":"2005","unstructured":"Premalatha B, Rajgopal G. Cancer\u2014an Ayurvedic perspective. Pharmacol Res. 2005;51(1):19\u201330.","journal-title":"Pharmacol Res"},{"issue":"4","key":"29_CR35","doi-asserted-by":"crossref","first-page":"e60338","DOI":"10.1371\/journal.pone.0060338","volume":"8","author":"X Li","year":"2012","unstructured":"Li X, Yang G, Li X, Zhang Y, Yang J, Chang J, et al. Traditional Chinese medicine in cancer care: a review of controlled clinical studies published in Chinese. PLoS One. 2012;8(4):e60338.","journal-title":"PLoS One"},{"key":"29_CR36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0367-326X(00)00305-1","volume":"72","author":"M Cu\u00e9llar","year":"2001","unstructured":"Cu\u00e9llar M, Giner R, Recio M, M\u00e1\u00f1ez S, R\u00edos J. Topical anti-inflammatory activity of some Asian medicinal plants used in dermatological disorders. Fitoterapia. 2001;72:221\u20139.","journal-title":"Fitoterapia"},{"key":"29_CR37","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1593\/neo.05745","volume":"8","author":"G Garcia","year":"2006","unstructured":"Garcia G, Nicole A, Bhaskaran S, Gupta A, Kyprianou N, Kumar A. Akt- and CREB-mediated prostate cancer cell proliferation inhibition by Nexrutine, a Phellodendron amurense extract. Neoplasia (New York, NY). 2006;8:523\u201333.","journal-title":"Neoplasia (New York, NY)"},{"key":"29_CR38","doi-asserted-by":"crossref","unstructured":"Akira I, Takayuki N, Hisao U. Indolopyridoquinazoline, furoquinoline and canthinone type alkaloids from Phellodendron amurense callus tissues. Phytochemistry. 1998;48:285\u201391.","DOI":"10.1016\/S0031-9422(97)01130-8"},{"key":"29_CR39","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s12272-012-0612-y","volume":"35","author":"J Ryuk","year":"2012","unstructured":"Ryuk J, Zheng M, Lee M, Seo C, Li Y, Lee S, et al. Discrimination of Phellodendron amurense and P. chinense based on DNA analysis and the simultaneous analysis of alkaloids. Arch Pharm Res. 2012;35:1045\u201354.","journal-title":"Arch Pharm Res"},{"key":"29_CR40","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.phymed.2012.09.028","volume":"20","author":"Y-F Xian","year":"2013","unstructured":"Xian Y-F, Lin Z-X, Ip S-P, Su Z-R, Chen J-N, Lai X-P. Comparison the neuropreotective effect of cortex Phellodendri chinensis and cortex Phellodendri amurensis against beta-amyloid-induced neurotoxicity in PC12 cells. Phytomedicine. 2013;20:187\u201393.","journal-title":"Phytomedicine"},{"key":"29_CR41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1475-2891-8-38","volume":"8","author":"J Oben","year":"2009","unstructured":"Oben J, Enonchong E, Kothari S, Chambliss W, Garrison R, Dolnick D. Phellodendron and citrus extracts benefit joint health in osteoarthritis patients: a pilot, double-blind, placebo-controlled study. Nutr J. 2009;8:38.","journal-title":"Nutr J"},{"key":"29_CR42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1550-2783-10-37","volume":"10","author":"S Talbott","year":"2013","unstructured":"Talbott S, Talbott J, Pugh M. Effect of Magnolia officinalis and Phellodendron amurense (Relora\u00ae) on cortisol and psychological mood state in moderately stressed subjects. J Int Soc Sports Nutr. 2013;10:37.","journal-title":"J Int Soc Sports Nutr"},{"key":"29_CR43","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/pros.20899","volume":"69","author":"S Muralimanoharan","year":"2009","unstructured":"Muralimanoharan S, Kunnumakkara A, Shylesh B, Kulkarni K, Haiyan X, Ming H, et al. Butanol fraction containing berberine or related compound from nexrutine inhibits NFkappaB signaling and induces apoptosis in prostate cancer cells. Prostate. 2009;69:494\u2013504.","journal-title":"Prostate"},{"key":"29_CR44","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1158\/1078-0432.CCR-06-2974","volume":"13","author":"A Kumar","year":"2007","unstructured":"Kumar A, Bhaskaran S, Ganapathy M, Crosby K, Davis M, Kochunov P, et al. Akt\/cAMP-responsive element binding protein\/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract. Clin Cancer Res. 2007;13:2784\u201394.","journal-title":"Clin Cancer Res"},{"key":"29_CR45","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1080\/01635581.2013.780627","volume":"66","author":"G Yan","year":"2013","unstructured":"Yan G, Lanza-Jacoby S, Wang C. Nexrutine inhibits survival and induces G1 cell cycle arrest, which is associated with apoptosis or autophagy depending on the breast cancer cell line. Nutr Cancer. 2013;66:506\u201316.","journal-title":"Nutr Cancer"},{"key":"29_CR46","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1093\/carcin\/bgs219","volume":"33","author":"R Kumar","year":"2012","unstructured":"Kumar R, Das M, Ansari KM. Nexrutine(R) inhibits tumorigenesis in mouse skin and induces apoptotic cell death in human squamous carcinoma A431 and human melanoma A375 cells. Carcinogenesis. 2012;33:1909\u201318.","journal-title":"Carcinogenesis"},{"key":"29_CR47","first-page":"857","volume":"30","author":"R Ghosh","year":"2010","unstructured":"Ghosh R, Graham H, Rivas P, Tan X, Crosby K, Bhaskaran S, et al. Phellodendron amurense bark extract prevents progression of prostate tumors in transgenic adenocarcinoma of mouse prostate: potential for prostate cancer management. Anticancer Res. 2010;30:857\u201365.","journal-title":"Anticancer Res"},{"key":"29_CR48","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1593\/neo.07502","volume":"9","author":"R Ghosh","year":"2007","unstructured":"Ghosh R, Garcia G, Crosby K, Inoue H, Thompson I, Troyer D, et al. Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for Nexrutine. Neoplasia (New York, NY). 2007;9:893\u20139.","journal-title":"Neoplasia (New York, NY)"},{"key":"29_CR49","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.18632\/oncotarget.1810","volume":"5","author":"J Gong","year":"2014","unstructured":"Gong J, Mu\u00f1oz AR, Chan D, Ghosh R, Kumar AP. STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth. Oncotarget. 2014;5:2529\u201341. This was the first study elucidating the effect of Nexrutine\u00ae on autophagy and ROS in pancreatic cancer.","journal-title":"Oncotarget"},{"key":"29_CR50","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1158\/1078-0432.CCR-13-1664","volume":"20","author":"J Gong","year":"2014","unstructured":"Gong J, Xie J, Bedolla R, Rivas P, Chakravarthy D, Freeman JW, et al. Combined targeting of STAT3\/NF\u2013\u03baB\/COX-2\/EP4 for effective management of pancreatic cancer. Clin Cancer Res. 2014;20:1259\u201373. The benefits of Nexrutine\u00ae for pancreatic cancer treatment was established and it was shown that Nexrutine\u00ae can reduce fibrosis, which has important implication for therapeutic resistance.","journal-title":"Clin Cancer Res"},{"key":"29_CR51","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2174\/156800910791208535","volume":"10","author":"X Xiao","year":"2010","unstructured":"Xiao X, Li BX, Mitton B, Ikeda A, Sakamoto KM. Targeting CREB for cancer therapy: friend or foe. Curr Cancer Drug Targets. 2010;10:384\u201391.","journal-title":"Curr Cancer Drug Targets"},{"key":"29_CR52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11\u201322.","journal-title":"Cancer Cell"},{"key":"29_CR53","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2174\/156800907781662248","volume":"7","author":"Y Wang","year":"2007","unstructured":"Wang Y, Kreisberg JI, Ghosh PM. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase\/Akt pathway in prostate cancer. Curr Cancer Drug Targets. 2007;7:591\u2013604.","journal-title":"Curr Cancer Drug Targets"},{"issue":"11","key":"29_CR54","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1158\/1535-7163.MCT-13-0032","volume":"12","author":"C Thomas","year":"2013","unstructured":"Thomas C, Lamoureux F, Crafter C, Davies BR, Beralidi E, Fazli L, et al. Synergistic targeting of PI3K\/AKT-pathway and androgen-receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther. 2013;12(11):2342\u201355.","journal-title":"Mol Cancer Ther"},{"key":"29_CR55","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1677\/JOE-09-0270","volume":"204","author":"H-ZZ Sun","year":"2010","unstructured":"Sun H-ZZ, Yang T-WW, Zang W-JJ, Wu S-FF. Dehydroepiandrosterone-induced proliferation of prostatic epithelial cell is mediated by NFKB via PI3K\/AKT signaling pathway. J Endocrinol. 2010;204:311\u20138.","journal-title":"J Endocrinol"},{"issue":"24","key":"29_CR56","doi-asserted-by":"crossref","first-page":"8460","DOI":"10.1158\/1078-0432.CCR-04-0764","volume":"10","author":"F Vincent","year":"2004","unstructured":"Vincent F, Laurent L, Louis RB, Pierre K, Anne-Marie Mes M, Fred S. Nuclear factor\u2013\u03baB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res. 2004;10(24):8460\u20134.","journal-title":"Clin Cancer Res"},{"key":"29_CR57","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bone.2010.05.038","volume":"48","author":"R Lee","year":"2011","unstructured":"Lee R, Saylor P, Smith M. Treatment and prevention of bone complications from prostate cancer. Bone. 2011;48:88\u201395.","journal-title":"Bone"},{"key":"29_CR58","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/cncr.25467","volume":"117","author":"ZA Alicikus","year":"2011","unstructured":"Alicikus ZA, Yamada Y, Zhang Z, Pei X, Hunt M, Kollmeier M, et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer. 2011;117:1429\u201337.","journal-title":"Cancer"},{"key":"29_CR59","doi-asserted-by":"crossref","unstructured":"Swanson GP, Jones WE, Ha CS, Jenkins CA, Kumar AP, Basler J. Tolerance of Phellodendron amurense bark extract (Nexrutine\u00ae) in patients with human prostate cancer. Phytother Res. 2015;29:40\u201342.","DOI":"10.1002\/ptr.5221"},{"key":"29_CR60","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","volume":"32","author":"T Karantanos","year":"2013","unstructured":"Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32:5501\u201311.","journal-title":"Oncogene"},{"key":"29_CR61","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nrgastro.2012.115","volume":"9","author":"M Erkan","year":"2012","unstructured":"Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol. 2012;9:454\u201367.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"29_CR62","doi-asserted-by":"crossref","unstructured":"Oyajobi BO, Gupta A, McCluskey B, Mann M and Kumar AP. Antitumor effect of Nexrutine, a Phellodendron amurense bark extract in multiple myeloma. 102nd Annual Meeting of American Association for Cancer Research; 2011, Abstract 4216.","DOI":"10.1158\/1538-7445.AM2011-4216"},{"issue":"3","key":"29_CR63","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/carcin\/bgp014","volume":"30","author":"G Alexander","year":"2009","unstructured":"Alexander G, Helena JMS, Amy EM, Heather RR, Ann CW, Christos P, et al. The COX-2\/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009;30(3):377\u201386.","journal-title":"Carcinogenesis"},{"key":"29_CR64","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/35085068","volume":"2","author":"B Mayr","year":"2001","unstructured":"Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol. 2001;2:599\u2013609.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"29_CR65","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11033-007-9085-3","volume":"34","author":"Z Xiongfei","year":"2007","unstructured":"Xiongfei Z, Jingjing Z, Xiaomin Y, Xiao H. Several transcription factors regulate COX-2 gene expression in pancreatic \u03b2-cells. Mol Biol Rep. 2007;34(3):199\u2013206.","journal-title":"Mol Biol Rep"},{"issue":"2 Pt 2","key":"29_CR66","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1097\/01.ju.0000107839.06670.27","volume":"171","author":"JW Basler","year":"2004","unstructured":"Basler JW, Piazza GA. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol. 2004;171(2 Pt 2):S59\u201362.","journal-title":"J Urol"},{"key":"29_CR67","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10787-009-8049-8","volume":"17","author":"RE Harris","year":"2009","unstructured":"Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology. 2009;17:55\u201367.","journal-title":"Inflammopharmacology"},{"key":"29_CR68","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-med-121211-091527","volume":"64","author":"CA Gilbert","year":"2012","unstructured":"Gilbert CA, Slingerland JM. Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annu Rev Med. 2012;64:45\u201357.","journal-title":"Annu Rev Med"},{"key":"29_CR69","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc1408","volume":"4","author":"EC Eugenia","year":"2004","unstructured":"Eugenia EC, Rudolf K. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579\u201391.","journal-title":"Nat Rev Cancer"},{"key":"29_CR70","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.chroma.2007.12.024","volume":"1180","author":"S Wu","year":"2008","unstructured":"Wu S, Yang L, Gao Y, Liu X, Liu F. Multi-channel counter-current chromatography for high-throughput fractionation of natural products for drug discovery. J Chromatogr A. 2008;1180:99\u2013107.","journal-title":"J Chromatogr A"},{"key":"29_CR71","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.drudis.2008.07.004","volume":"13","author":"A Harvey","year":"2008","unstructured":"Harvey A. Natural products in drug discovery. Drug Discov Today. 2008;13:894\u2013901.","journal-title":"Drug Discov Today"},{"issue":"2","key":"29_CR72","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.compbiolchem.2005.11.003","volume":"30","author":"Y Cheng","year":"2006","unstructured":"Cheng Y, Wang Y, Wang X. A causal relationship discovery-based approach to identifying active components of herbal medicine. Comput Biol Chem. 2006;30(2):148\u201354.","journal-title":"Comput Biol Chem"},{"key":"29_CR73","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s11517-008-0323-1","volume":"46","author":"Y Wang","year":"2008","unstructured":"Wang Y, Jin Y, Zhou C, Qu H, Cheng Y. Discovering active compounds from mixture of natural products by data mining approach. Med Biol Eng Comput. 2008;46:605\u201311.","journal-title":"Med Biol Eng Comput"}],"container-title":["Current Pharmacology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40495-015-0029-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40495-015-0029-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40495-015-0029-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T05:07:53Z","timestamp":1566450473000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40495-015-0029-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,21]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["29"],"URL":"https:\/\/doi.org\/10.1007\/s40495-015-0029-7","relation":{},"ISSN":["2198-641X"],"issn-type":[{"value":"2198-641X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,21]]}}}